KPTIのニュース
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stock crossing the finish line today 2023/02/21 17:48:00 US Post News
Karyopharm Therapeutics Inc. (KPTI)’s stock has witnessed a price declined of -5.63% from the previous close with its current price standing at $3.35. Its current price is -77.26% under its 52-week high of $14.73 and 36.73% more than its 52-week low of $2.45. Based on the past 30-day period, the stock price is -12.53% below […]
Let’s Start With The Stock Forecast For Karyopharm Therapeutics Inc. (NASDAQ: KPTI) 2023/02/21 13:00:00 Marketing Sentinel
In the last trading session, 1.67 million Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares changed hands as the company’s beta touched 0.02. With the company’s per share price at $3.55 changed hands at -$0.04 or -1.11% during last session, the market valuation stood at $406.40M. KPTI’s last price was a discount, traded about -314.93% off its 52-week … Let’s Start With The Stock Forecast For Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Read More »
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy 2023/02/21 13:00:00 PR Newswire
Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer…
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy 2023/02/21 13:00:00 Karyopharm Therapeutics
Karyopharm Therapeutics (KPTI) Q4 2022 Earnings Call Transcript 2023/02/15 19:00:37 The Motley Fool
KPTI earnings call for the period ending December 31, 2022.
KPTI stock gains as company wins FDA’s Orphan Drug status for cancer drug (NASDAQ:KPTI) 2022/05/26 17:04:53 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) on Thursday granted its Orphan Drug Designation for Karyopharm Therapeutics (KPTI) for the company’s leading product, selinexor…
Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma 2022/05/25 12:35:58 Seeking Alpha
Karyopharm Therapeutics (KPTI) and the European Myeloma Network ((EMN)), a collaboration of centers for multiple myeloma in Europe and Australia, said the first patient was dosed in…
Earnings Scheduled For May 5, 2022 2022/05/05 08:43:22 Benzinga
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ: MIRM ) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million. • Bluegreen Vacations (NYSE: BVH ) is estimated to report quarterly earnings at $0.53 per share on revenue of $181.17 million. • Selecta Biosciences (NASDAQ: SELB ) is expected to report quarterly loss at $0.11 per share on revenue of $13.12 million. • Alpha Metallurgical (NYSE: AMR ) is projected to report quarterly earnings at $19.04 per share on revenue of $944.95 million. • DigitalBridge Group (NYSE: DBRG ) is projected to report quarterly loss at $0.03 per share on revenue of $259.60 million. • Madison Square Garden (NYSE: MSGS ) is projected to report quarterly earnings at $1.59 per share on revenue of $332.95 million. • Intellia Therapeutics (NASDAQ: NTLA ) is likely to report quarterly loss at $1.10 per share on revenue of $8.54 million. • InterDigital (NASDAQ: IDCC ) is estimated to report quarterly earnings at $0.73 per share on revenue of $97.
FY2021 EPS Estimates for Karyopharm Therapeutics Inc. Boosted by Wedbush (NASDAQ:KPTI) 2021/12/24 11:58:41 Transcript Daily
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Investment analysts at Wedbush upped their FY2021 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a note issued to investors on Tuesday, December 21st. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.81) per share for the year, up from their prior estimate of []
Karyopharm, Menarini Ink Over $200M Licensing Pact For Selinexor In Europe, Other Territories 2021/12/21 20:09:57 Benzinga
Karyopharm Therapeutics Inc (NASDAQ: KPTI ) and the Menarini Group entered an exclusive licensing agreement whereby Menarini will commercialize Karyopharm''s Nexpovio (selinexor) in Europe and other key global territories. Under the agreement terms, Menarini received exclusive rights to commercialize Nexpovio for oncology indications in the European Union and other European countries, Latin America Full story available on Benzinga.com
Is Karyopharm Therapeutics Inc. (NASDAQ: KPTI) A Great Stock To Invest In? 2021/12/21 18:00:00 Stocks Register
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded at $6.47 at last check on Tuesday, December 21, made an upward move of 1.65% on its previous day’s price. Looking at the stock we see that its previous close was $6.36 and the beta (5Y monthly) reads 0.20 with the day’s price range being $5.88 – $6.48. In terms … Is Karyopharm Therapeutics Inc. (NASDAQ: KPTI) A Great Stock To Invest In? Read More »
Karyopharm Therapeutics Inc. (KPTI) Gains 3.41%, Causing Bears To Win 2021/12/21 13:30:00 Marketing Sentinel
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has a beta value of -0.03 and has seen 1.79 million shares traded in the last trading session. The company, currently valued at $468.80M, closed the last trade at $6.36 per share which meant it gained $0.21 on the day or 3.41% during that session. The KPTI stock price is -183.02% … Karyopharm Therapeutics Inc. (KPTI) Gains 3.41%, Causing Bears To Win Read More »
Brokerages Expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Will Post Quarterly Sales of $29.61 Million 2021/12/20 09:20:41 Dakota Financial News
Brokerages expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to announce sales of $29.61 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Karyopharm Therapeutics earnings, with the lowest sales estimate coming in at $24.30 million and the highest estimate coming in at $38.69 million. Karyopharm Therapeutics posted sales of $35.10 million []